World’s leading biobanks join a global network to advance personalized healthcare research
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.
BC Platforms, the provider of a powerful data and technology platform for personalized healthcare, has added three new leading biobanks to its Global Data Partner Network, BCRQUEST.com: Generation Scotland (UK), Bialystok Biobank (Poland) and Biobank Graz (Austria).
The BCRQUEST.com platform enables researchers to efficiently access harmonized data while strictly adhering to global and local data privacy and security regulations.
The platform and its supporting framework facilitate collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.
The addition of these three new, high-quality biobanks brings the BCRQUEST.com network to almost 3.5 million consented patient healthcare records from nearly 10 countries in North America and Europe.
Bialystok Biobank focuses on clinical samples for cancer and specifically on new biomarkers for early diagnosis, as well as personalized therapy of cancer-based on genetic-molecular disorders.
Biobank Graz is one of the biggest biobanks in the world with 20 million tissue, blood and DNA samples from more than 1.2 million patients.
Generation Scotland is a population-based cohort designed to study the genetic and environmental determinants of health.
Dr Christian Gülly, COO, Biobank Graz, Medical University of Graz, Austria, commented: “We are excited to be collaborating with BC Platforms to securely share our data for the benefit of patients without compromising any privacy issues. We have been impressed by the BCRQUEST.com platform and its ability to analyse, integrate and share data in a secure manner and in line with the European General Data Protection Regulation (GDPR) to support researchers in developing personalized medicines.”
Given BC Platforms' strong focus on genetic and clinical data, Tero Silvola, CEO of BC Platforms described their growing network as a "unique" and "invaluable asset" for researchers and industry. Speaking of the new addition, he said: "This will progress the development of personalized healthcare for the benefit of patients, healthcare systems and research.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.